WASHINGTON, DC, January 8, 2013 — Arlington Capital Partners (www.arlingtoncap.com), a Washington, DC based private equity firm, today announced the sale of its portfolio company Cambridge Major Laboratories, Inc. (“Cambridge Major”) to publicly traded American Capital, Limited.
Headquartered in Germantown, Wisconsin, Cambridge Major is a leading global, chemistry-based contract research organization (“CRO”) providing comprehensive chemistry outsourcing solutions to a diverse customer base of over 150 companies, including some of the world’s largest pharmaceutical, small/mid-sized biotechnology, and generic drug companies. Cambridge Major offers customers a broad array of chemistry services, delivering a complete life cycle of capabilities including process chemistry, solid state chemistry, analytical services, active pharmaceutical ingredients (“API”) production services and regulatory services.
“We are delighted to have partnered with Cambridge Major’s management team to support the Company’s development into one of the leading independent producers of active pharmaceutical ingredients,” said Peter Manos, a Managing Partner at Arlington Capital Partners. “The Company’s preeminent position as a leading western-based science company, combined with strong industry drivers of greater discovery from biotech/emerging pharma companies and increasing outsourcing by large pharmaceutical companies to trusted partners like Cambridge Major, confirmed Arlington’s initial investment thesis”
Matt Altman, a Partner at Arlington Capital Partners, said, “Cambridge Major demonstrated tremendous growth during our ownership and we were pleased to provide significant strategic and capital support which facilitated both a large scale greenfield investment and an overseas acquisition. Arlington continued its tradition of backing strong management teams with valuable resources from our own industry experience and network.”
Brian Scanlan, Cambridge Major’s Chief Executive Officer, said, “Arlington Capital was a great partner for the business strategically as well as financially. Since Arlington’s investment in 2007, we have expanded our operations into Europe, built a new large scale commercialization facility in the U.S., increased revenue by more than 400% and increased EBITDA by more than 300%. We continue to be excited about the future of Cambridge Major and our new partnership with American Capital.”
About Cambridge Major Laboratories, Inc.
Cambridge Major Laboratories, Inc. (“Cambridge Major”) is a leading global chemistry outsourcing partner to the pharmaceutical and biotechnology industries. The Company produces pharmaceutical intermediates and Active Pharmaceutical Ingredients (API) from early preclinical development to commercial manufacture. Operating from FDA inspected facilities in the US and Europe, Cambridge Major is organized along five key Centers of Excellence including; Process Chemistry, GMP Manufacturing, Solid State Chemistry, Analytical Services, and Quality/Regulatory Compliance.
About Arlington Capital Partners
Arlington Capital Partners is a Washington, D.C.-based private equity firm with $1.5 billion of committed capital focused on middle market investment opportunities in growth industries including: healthcare services, aerospace/defense, government contracting, business services and software. The firm’s professionals and network have a unique combination of operating and private equity experience that enables Arlington to be a value-added investor. Arlington invests in companies in partnership with high quality management teams that are motivated to establish and/or advance their company’s position as leading competitors in their field. www.arlingtoncap.com
Peter Manos or Matt Altman
Arlington Capital Partners
5425 Wisconsin Avenue, Suite 200
Chevy Chase, MD 20815
(202) 337-7525 (fax)
SOURCE: Arlington Capital Partners